Relay Therapeutics cleared an efficacy benchmark in Phase 2 for zovegalisib, its PI3Kα inhibitor, in patients with vascular anomalies tied to rare genetic disease. The first Phase 2 data readout reportedly beat Wall Street expectations, widening Relay’s R&D prospects beyond oncology. The result supports continued development of zovegalisib in a setting where treatment options are limited and where mechanism-driven PI3Kα targeting can be clinically relevant. It also positions Relay to potentially differentiate from earlier-generation approaches aimed at vascular anomaly biology. For investors and trial planners, the key takeaway is that Relay is generating new evidence for a clinical path that could broaden the asset’s eventual label footprint or combination strategy.